Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar;14(6):e70619.
doi: 10.1002/cam4.70619.

Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020

Laure Vincent  1 , Olivier Decaux  2 , Aurore Perrot  3 , Bruno Royer  4 , Thomas Chalopin  5 , Arthur Bobin  6 , Margaret Macro  7 , Denis Caillot  8 , Lionel Karlin  9 , Caroline Jacquet  10 , Cécile Sonntag  11 , Mohamad Mohty  12 , Laurent Frenzel  13 , Arnaud Jaccard  14   15 , Salomon Manier  16 , Laurence Sanhes  17 , Driss Chaoui  18 , Philippe Moreau  19 , Ronan Garlantézec  20 , Nathalie Texier  21 , Chanaz Louni  22 , Zakaria Maarouf  22 , Herve Avet Loiseau  23 , Cyrille Hulin  24 , Karim Belhadj Merzoug  25
Affiliations

Real-World Outcomes of Newly Diagnosed Multiple Myeloma Patients Treated Before the Era of Anti-CD38 Antibodies: The EMMY Cohort From 2017 to 2020

Laure Vincent et al. Cancer Med. 2025 Mar.

Abstract

Aims/background: Recent agents have profoundly reshaped the multiple myeloma (MM) landscape. Their real-world impacts need to be assessed over the long term.

Methods: EMMY is a non-interventional, prospective dynamic cohort, conducted in France, since 2017, with 900 patients enrolled each year. Newly diagnosed MM (NDMM) who initiated a treatment from 2017 to 2020 are here described.

Results: A total of 1036 non-transplant eligible (NTE) patients (median age: 74.9 years) and 561 patients who received autologous stem cell transplantation (ASCT) (median age: 60.6 years) were enrolled. For ASCT patients, a shift in induction treatment from bortezomib-thalidomide-dexamethasone (VTd) (29.1%) to bortezomib-lenalidomide-dexamethasone (VRd) (55.1%) marked the period. Maintenance treatment with R after ASCT became a standard (75% of patients). In NTE patients, R-based regimens were increasingly used from 29.4% in 2017 (of whom Rd.: 17.0%, VRd: 10.6%) to 73.3% in 2020 (of whom Rd.: 21.8%, VRd: 48.5%). Median progression-free survival (mPFS) was 46.5 months (95% CI: 37.8-50.6) and 18.7 months (95% CI: 16.3-20.8) in ASCT and NTE patients, respectively. In the ASCT group, patients treated with and without R maintenance had a mPFS of 51.8 (95% CI: 44.1-NA) and 29.6 months (95% CI: 21.8-40.9), respectively. In the NTE group, the mPFS was 26.3 (95% CI: 21.9-30.9) and 14.6 months (95% CI: 11.9-17.7) in patients who received an R-based and non-R-based regimen, respectively. The estimated 48-month overall survival rates were 89% (95% CI: 84.5-92.2) and 63% (95% CI: 58.5-67.1) for ASCT and NTE patients, respectively.

Conclusions: The 2017-2020 period was marked by the expansion of R use in both NDMM ASCT and NTE patients.

Keywords: ASCT patients; NTE patients; first‐line therapy; multiple myeloma; real world.

PubMed Disclaimer

Conflict of interest statement

L.V. received honoraria from Janssen, BMS, Takeda, Sanofi, Pfizer; O.D. received honoraria from Janssen, BMS, GSK, Sanofi, Takeda, Roche and Gilead; A.P. received honoraria from Abbvie, Amgen, BMS, GSK, Janssen, Sanofi and Takeda; M.M. received honoraria from Janssen, Sanofi, GSK and Takeda; L.K. received honoraria from Amgen, BMS, Janssen, Takeda, Sanofi, Abbvie, Stemline and GSK; C.S. participate as expert in board of experts for BMS, Amgen, Janssen, Takeda and Sanofi; M.M. received honoraria from Janssen, Sanofi, BMS, Amgen, Takeda, GSK, Pfizer, Novartis, Jazz Pharmaceuticals, Stemline and Astellas; L.F. is a consultant for Pfizer, Roche, CSL Behring, Sobi, BioMarin Pharmaceutical, A.J. received honoraria from Abbvie, Pfizer and Janssen; S.M. is a consultant for AbbVie, Adaptative Biotechnology, Amgen, BMS, GSK, Janssen, Regeneron, Roche, Sanofi, Takeda; P.M. is a consultant and received honoraria from Janssen, BMS, Amgen, Abbvie, Sanofi and Takeda; L.C. et ZM are employees of IFM; C.H. received honoraria from Janssen, BMS, GSK, Takeda, Sanofi and Amgen; K.B.M. is a consultant and received honoraria for BMS, Janssen, Sanofi, Amgen and Abbvie. The other authors declare that they have no competing interests.

Figures

FIGURE 1
FIGURE 1
Combination therapy received in (A) patients with NDMM who received ASCT and (B) NDMM NTE patients with NDMM according to the year of treatment initiation. ASCT: autologous stem cell transplant; C: cyclophosphamide; d: dexamethasone; Dara: daratumumab; M: Melphalan; NDMM: newly diagnosed multiple myeloma; NTE: non‐transplant eligible; p: prednisolone; R: lenalidomide; T: Thalidomide; V: bortezomib.
FIGURE 2
FIGURE 2
PFS distributions with 95% confidence intervals in (A) NDMM patients who received ASCT; (B) ASCT patients with maintenance and no maintenance therapy after ASCT.
FIGURE 3
FIGURE 3
PFS distributions with 95% confidence intervals in (A) NDMM NTE patients; (B) NTE patients who received R‐ and non‐R‐based treatment; (C) NTE patients who initiated upfront therapy in 2017, 2018, 2019 and 2020.
FIGURE 4
FIGURE 4
PFS2 distributions with 95% confidence intervals(A) in patients with NDMM who received ASCT; (B) in NTE patients with NDMM; (C) NTE patients who received R‐ and non‐R‐based treatment as first‐line therapy.
FIGURE 5
FIGURE 5
Overall survival (OS) distributions with 95% confidence intervals (A) in patients with NDMM who received ASCT; (B) in NTE patients with NDMM and (C) in NTE patients who received R‐ and non‐R‐based first‐line treatment.
See this image and copyright information in PMC

References

    1. Ferlay J., Colombet M., Soerjomataram I., et al., “Cancer Incidence and Mortality Patterns in Europe: Estimates for 40 Countries and 25 Major Cancers in 2018,” European Journal of Cancer 103 (2018): 356–387. - PubMed
    1. Moreau P., San Miguel J., Sonneveld P., et al., “Multiple Myeloma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up,” Annals of Oncology 28, no. suppl_4 (2017): 52–61. - PubMed
    1. Siegel R. L., Miller K. D., and Jemal A., “Cancer Statistics, 2018,” CA: A Cancer Journal for Clinicians 68, no. 1 (2018): 7–30. - PubMed
    1. Usmani S. Z., Hoering A., Cavo M., et al., “Clinical Predictors of Long‐Term Survival in Newly Diagnosed Transplant Eligible Multiple Myeloma ‐ An IMWG Research Project,” Blood Cancer Journal 8 (2018): 123. - PMC - PubMed
    1. Dimopoulos M. A., Moreau P., Terpos E., et al., “EHA‐ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow‐Up†,” Annals of Oncology 32, no. 3 (2021): 309–322. - PubMed

MeSH terms